A Dark Vector Cognition product

Item 6. EXHIBITS

43K characters. Original on sec.gov · Markdown

Item 6. EXHIBITS

Reference is made to the Exhibit Index included herein.

Exhibit Index

The following exhibits are filed or furnished herewith or incorporated by reference:

Exhibit NumberDescription of DocumentFiled / Furnished / Incorporated by Reference
2.1Agreement and Plan of Merger, dated February 11, 2024, among CymaBay Therapeutics, Inc., Registrant and Pacific Merger Sub, Inc.Incorporated herein by reference to an exhibit to our Form 8-K filed on February 12, 2024
2.2Agreement and Plan of Merger, dated February 22, 2026, among Arcellx, Inc., Registrant and Ravens Sub, Inc.Incorporated herein by reference to an exhibit to our Form 8-K filed on February 23, 2026
3.1Restated Certificate of Incorporation of RegistrantIncorporated herein by reference to an exhibit to our Form 8-K filed on May 9, 2024
3.2Amended and Restated Bylaws of RegistrantIncorporated herein by reference to an exhibit to our Form 8-K filed on August 4, 2025
4.1Reference is made to Exhibit 3.1 and Exhibit 3.2
4.2Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as TrusteeIncorporated herein by reference to an exhibit to our Form 8-K filed on April 1, 2011
4.3First Supplemental Indenture related to Senior Notes, dated as of March 30, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including form of Senior Notes)Incorporated herein by reference to an exhibit to our Form 8-K filed on April 1, 2011
4.4Second Supplemental Indenture related to Senior Notes, dated as of December 13, 2011, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2041 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on December 13, 2011
4.5Third Supplemental Indenture related to Senior Notes, dated as of March 7, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2044 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on March 7, 2014
4.6Fourth Supplemental Indenture related to Senior Notes, dated as of November 17, 2014, between Registrant and Wells Fargo, National Association, as Trustee (including Form of 2045 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on November 17, 2014
4.7Fifth Supplemental Indenture, dated as of September 14, 2015, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2026 Note, Form of 2035 Note and Form of 2046 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on September 14, 2015
4.8Sixth Supplemental Indenture, dated as of September 20, 2016, between Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2027 Note, Form of 2036 Note and Form of 2047 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on September 20, 2016
4.9Eighth Supplemental Indenture, dated as of September 30, 2020, between the Registrant and Wells Fargo Bank, National Association, as Trustee (including Form of 2027 Note, Form of 2030 Note, Form of 2040 Note, and Form of 2050 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on September 30, 2020
4.1Ninth Supplemental Indenture, dated as of September 14, 2023, between the Registrant and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee (including Form of 2033 Note and Form of 2053 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on September 14, 2023
4.11Tenth Supplemental Indenture, dated as of November 20, 2024, between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee (including Form of 2029 Note, Form of 2035 Note, Form of 2054 Note and Form 2064 Note)Incorporated herein by reference to an exhibit to our Form 8-K filed on November 20, 2024
4.12Description of Registrant’s SecuritiesIncorporated herein by reference to an exhibit to our Form 10-K filed on February 25, 2020
10.1*Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017Incorporated herein by reference to an exhibit to our Form 8-K filed on May 12, 2017
10.2*Amendment No. 1 to Gilead Sciences, Inc. 2004 Equity Incentive Plan, amended and restated May 10, 2017Incorporated herein by reference to an exhibit to our Form 10-K filed on February 25, 2021
10.3*Gilead Sciences, Inc. 2022 Equity Incentive Plan, amended and restated April 30, 2026Incorporated herein by reference to an exhibit to our Form 8-K filed on May 4, 2026
10.4*Form of employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2011 through 2018)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 9, 2011
10.5*Form of global employee stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2019
10.6*Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2019)Incorporated herein by reference to an exhibit to our Form 10-Q filed on November 5, 2019
10.7*Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2020)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 6, 2020
10.8*Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for grants made in 2021)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 6, 2021
10.9*Form of global employee stock option agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 4, 2022
10.10*Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 8, 2022
10.11*Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2023)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.12*Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2024)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 8, 2024
10.13*Form of global employee stock option agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants commencing in 2025)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 7, 2025
10.14*Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2014 through 2018)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 4, 2014
10.15*Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2019)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2019
10.16*Form of non-employee director stock option agreement under 2004 Equity Incentive Plan (for grants made in 2020 and 2021)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2020
10.17*Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants made in 2022)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 8, 2022
10.18*Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants made in 2023)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 4, 2023
10.19*Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants made in 2024)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 8, 2024
10.20*Form of non-employee director stock option agreement under 2022 Equity Incentive Plan (for grants commencing in 2025)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 7, 2025
10.21*Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants made in 2023)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.22*Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants made in 2024)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 8, 2024
10.23*Form of performance share award agreement - TSR Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2025)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 7, 2025
10.24*Form of performance share award agreement - Revenue Goals (U.S.) under 2022 Equity Incentive Plan (for grants made in 2023)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.25*Form of performance share award agreement - Revenue Goals (U.S.) under 2022 Equity Incentive Plan (for grants made in 2024)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 8, 2024
10.26*Form of performance share award agreement – Adjusted EPS Growth Goals (U.S.) under 2022 Equity Incentive Plan (for grants made in 2025)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 7, 2025
10.27*Form of performance share award agreement – Adjusted EPS Growth Goals (U.S.) under 2022 Equity Incentive Plan (for grants commencing in 2026)Filed herewith
10.28*Form of global employee restricted stock unit issuance agreement under 2004 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 4, 2022
10.29*Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for certain grants made in 2022)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 8, 2022
10.30*Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants made in 2023)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.31*Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants made in 2024)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 8, 2024
10.32*Form of global employee restricted stock unit agreement under 2022 Equity Incentive Plan (4 year vest) (for grants commencing in 2025)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 7, 2025
10.33*Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grants made in 2024)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 8, 2024
10.34*Form of non-employee director restricted stock unit agreement under 2022 Equity Incentive Plan (for grants commencing in 2025)Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 7, 2025
10.35*Gilead Sciences, Inc. 2018 Equity Incentive Plan, amended and restated April 7, 2020Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2020
10.36*Gilead Sciences, Inc. Employee Stock Purchase Plan, amended and restated January 25, 2023Incorporated herein by reference to an exhibit to our Form 8-K filed on May 5, 2023
10.37*Gilead Sciences, Inc. 2005 Deferred Compensation Plan, amended and restated April 19, 2016Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2019
10.38*Gilead Sciences, Inc. Severance Plan, amended and restated July 29, 2025Incorporated herein by reference to an exhibit to our Form 10-Q filed on November 7, 2025
10.39*Gilead Sciences, Inc. Corporate Annual Incentive Plan, amended and restated August 1, 2023Incorporated herein by reference to an exhibit to our Form 10-Q filed on November 7, 2023
10.40*Offer Letter between Registrant and Daniel O’Day, dated November 30, 2018Incorporated herein by reference to an exhibit to our Form 8-K filed on December 10, 2018
10.41*Stock option agreement for Daniel O’Day under 2004 Equity Incentive PlanIncorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2019
10.42*Form of restricted stock unit issuance agreement for Daniel O’Day (in 2019) under 2004 Equity Incentive PlanIncorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2019
10.43*Offer Letter between Registrant and Johanna Mercier, dated May 21, 2019Incorporated herein by reference to an exhibit to our Form 10-Q filed on August 6, 2019
10.44*Global stock option agreement for Johanna Mercier (in 2019) under 2004 Equity Incentive PlanIncorporated herein by reference to an exhibit to our Form 10-Q filed on May 6, 2020
10.45*Restricted stock unit issuance agreement for Johanna Mercier (for Performance Objectives in 2019-2020) under 2004 Equity Incentive PlanIncorporated herein by reference to an exhibit to our Form 10-Q filed on May 6, 2020
10.46*Offer Letter between Registrant and Dietmar Berger, dated November 14, 2024Filed herewith
10.47*Global restricted stock unit agreement for Dietmar Berger under 2022 Equity Incentive Plan (3 year vest)Filed herewith
10.48*Offer Letter between Registrant and Deborah Telman, dated June 2, 2022Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.49*Global stock option agreement for Deborah Telman under 2022 Equity Incentive PlanIncorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.50*Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (3 year vest)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.51*Global restricted stock unit issuance agreement for Deborah Telman under 2022 Equity Incentive Plan (4 year vest)Incorporated herein by reference to an exhibit to our Form 10-Q filed on May 3, 2023
10.52*Severance and General Release Agreement between Registrant and Deborah Telman, dated November 16, 2025Incorporated herein by reference to an exhibit to our Form 10-K filed on February 24, 2026
10.53*Form of Indemnity Agreement entered into between Registrant and its directors and executive officersIncorporated herein by reference to an exhibit to our Form S-1 (No. 33-55680), as amended
10.54*Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employeesIncorporated herein by reference to an exhibit to our Form S-1 (No. 33-55680), as amended
10.55*Form of Employee Proprietary Information and Invention Agreement entered into between Registrant and certain of its officers and key employees (revised September 2006)Incorporated herein by reference to an exhibit to our Form 10-K filed on February 27, 2007
10.56*,+Amendment Agreement, dated October 25, 1993, between Registrant, the Institute of Organic Chemistry and Biochemistry (IOCB) and Rega Stichting v.z.w. (REGA), together with the following exhibits: the License Agreement, dated December 15, 1991, between Registrant, IOCB and REGA (the 1991 License Agreement); the License Agreement, dated October 15, 1992, between Registrant, IOCB and REGA (the October 1992 License Agreement); and the License Agreement, dated December 1, 1992, between Registrant, IOCB and REGA (the December 1992 License Agreement)Incorporated herein by reference to an exhibit to our Form 10-K for our fiscal year ended March 31, 1994
10.57*,+Amendment Agreement between Registrant and IOCB/REGA, dated December 27, 2000, amending the 1991 License Agreement and the December 1992 License AgreementIncorporated herein by reference to an exhibit to our Form 10-K filed on March 20, 2001
10.58+Sixth Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated August 18, 2006, amending the October 1992 License Agreement and the December 1992 License AgreementIncorporated herein by reference to an exhibit to our Form 10-Q filed on November 6, 2006
10.59+Seventh Amendment Agreement to the License Agreement, between IOCB/REGA and Registrant, dated July 1, 2013, amending the October 1992 License Agreement and the December 1992 License AgreementIncorporated herein by reference to an exhibit to our Form 10-Q filed on October 31, 2013
10.60+Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University, dated May 6, 1999Incorporated herein by reference to an exhibit to Triangle Pharmaceuticals, Inc.’s Form 10-Q/A filed on November 3, 1999
10.61+Royalty Sale Agreement by and among Registrant, Emory University and Investors Trust & Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July 18, 2005Incorporated herein by reference to an exhibit to our Form 10-Q filed on November 4, 2005
10.62+Amended and Restated License Agreement by and between Registrant, Emory University and Investors Trust & Custodial Services (Ireland) Limited, solely in its capacity as Trustee of Royalty Pharma, dated July 21, 2005Incorporated herein by reference to an exhibit to our Form 10-Q filed on November 4, 2005
10.63++Amended and Restated EVG License Agreement by and between Japan Tobacco Inc. and Registrant, dated November 29, 2018Incorporated herein by reference to an exhibit to our Form 10-K/A filed on April 18, 2019
10.64++Master Agreement by and between Registrant, Gilead Sciences K.K. and Japan Tobacco Inc., dated November 29, 2018Incorporated herein by reference to an exhibit to our Form 10-K/A filed on April 18, 2019
10.65+Amended and Restated Collaboration Agreement by and among Registrant, Gilead Sciences Ireland UC (formerly Gilead Sciences Limited) and Janssen R&D Ireland, dated December 23, 2014Incorporated herein by reference to an exhibit to our Form 10-K filed on February 25, 2015
10.66+License Agreement by and among Kite Pharma, Inc., Cabaret Biotech Ltd. and Dr. Zelig Eshhar, dated December 12, 2013Incorporated herein by reference to an exhibit to Kite Pharma, Inc.’s Form S-1/A (No. 333-196081) filed on June 17, 2014
10.67++Option, License and Collaboration Agreement by and between Galapagos NV and Registrant, dated July 14, 2019Incorporated herein by reference to an exhibit to our Form 10-Q filed on November 5, 2019
31.1Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amendedFiled herewith
31.2Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amendedFiled herewith
32Certifications of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)Furnished herewith
101.INSXBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentFiled herewith
101.SCHInline XBRL Taxonomy Extension Schema DocumentFiled herewith
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentFiled herewith
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentFiled herewith
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentFiled herewith
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith
104Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)
  • Management contract or compensatory plan or arrangement.

+ Certain confidential portions of this Exhibit were omitted by means of marking such portions with an asterisk (the Mark). This Exhibit has been filed separately with the Secretary of U.S. Securities and Exchange Commission without the Mark pursuant to Registrant’s Application Requesting Confidential Treatment under Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

++ Certain portions of this Exhibit were omitted by means of marking such portions with the Mark because the identified portions are (i) private or confidential and (ii) not material.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GILEAD SCIENCES, INC.
(Registrant)
Date:May 7, 2026/s/ DANIEL P. O’DAY
Daniel P. O’Day Chairman and Chief Executive Officer (Principal Executive Officer)
Date:May 7, 2026/s/ ANDREW D. DICKINSON
Andrew D. Dickinson Chief Financial Officer (Principal Financial Officer)

Previous: Item 5. OTHER INFORMATION